Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2

David R. Adams, Salha Tawati, Giacomo Berretta, Paula Lopez Rivas, Jessica Baiget, Zhong Jiang, Aisha Alsfouk, Simon P. MacKay, Nigel J. Pyne, Susan Pyne

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sphingosine kinase enzymes (SK1 and SK2) catalyze the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding "J-channel" in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.

LanguageEnglish
Pages3658-3676
Number of pages19
JournalJournal of Medicinal Chemistry
Volume62
Issue number7
Early online date19 Mar 2019
DOIs
Publication statusPublished - 11 Apr 2019

Fingerprint

Protein Isoforms
Ligands
Lipids
Sphingosine
Foot
Amino Acid Sequence
sphingosine kinase
PF-543
sphingosine 1-phosphate
sulfurylase kinase

Keywords

  • sphingosine kinase
  • SK1
  • SK2

Cite this

Adams, David R. ; Tawati, Salha ; Berretta, Giacomo ; Rivas, Paula Lopez ; Baiget, Jessica ; Jiang, Zhong ; Alsfouk, Aisha ; MacKay, Simon P. ; Pyne, Nigel J. ; Pyne, Susan. / Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 7. pp. 3658-3676.
@article{c9ce3732a24e448c936d2a89f699608f,
title = "Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2",
abstract = "Sphingosine kinase enzymes (SK1 and SK2) catalyze the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding {"}J-channel{"} in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.",
keywords = "sphingosine kinase, SK1, SK2",
author = "Adams, {David R.} and Salha Tawati and Giacomo Berretta and Rivas, {Paula Lopez} and Jessica Baiget and Zhong Jiang and Aisha Alsfouk and MacKay, {Simon P.} and Pyne, {Nigel J.} and Susan Pyne",
year = "2019",
month = "4",
day = "11",
doi = "10.1021/acs.jmedchem.9b00162",
language = "English",
volume = "62",
pages = "3658--3676",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2. / Adams, David R.; Tawati, Salha; Berretta, Giacomo; Rivas, Paula Lopez; Baiget, Jessica; Jiang, Zhong; Alsfouk, Aisha; MacKay, Simon P.; Pyne, Nigel J.; Pyne, Susan.

In: Journal of Medicinal Chemistry, Vol. 62, No. 7, 11.04.2019, p. 3658-3676.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2

AU - Adams, David R.

AU - Tawati, Salha

AU - Berretta, Giacomo

AU - Rivas, Paula Lopez

AU - Baiget, Jessica

AU - Jiang, Zhong

AU - Alsfouk, Aisha

AU - MacKay, Simon P.

AU - Pyne, Nigel J.

AU - Pyne, Susan

PY - 2019/4/11

Y1 - 2019/4/11

N2 - Sphingosine kinase enzymes (SK1 and SK2) catalyze the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding "J-channel" in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.

AB - Sphingosine kinase enzymes (SK1 and SK2) catalyze the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding "J-channel" in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.

KW - sphingosine kinase

KW - SK1

KW - SK2

U2 - 10.1021/acs.jmedchem.9b00162

DO - 10.1021/acs.jmedchem.9b00162

M3 - Article

VL - 62

SP - 3658

EP - 3676

JO - Journal of Medicinal Chemistry

T2 - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -